Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Immunology   Volumes    Volume 18 
Clinical outcome of allergen-specific subcutaneous immunotherapy vaccines in respiratory allergic diseases: 2-year study at Mansoura University, Egypt
Amina Abd El-Maksoud, Mohammed Abubakr Abu El-Enin, Fathalla Belal, Waleed N. Elmazny, Saad A. M. Moghannem
Pages: 43 - 55
Number of pages: 13
Current Trends in Immunology
Volume 18 

Copyright © 2017 Research Trends. All rights reserved

To assess the clinical efficacy and safety of allergen-specific subcutaneous immunotherapy (SCIT) practice in Mansoura university, a single center, large sample, randomized, controlled, two-parallel group study was conducted on 2197 patients with evidence of any of the respiratory allergic diseases such as allergic asthma, allergic rhinitis, allergic rhino-conjunctivitis and combined airway disease. 1997 patients received SCIT and 200 patients were treated with medication only (pharmacotherapy group) as a positive control. Clinical assessment using symptom scores and medication scores, spirometric lung function tests (forced expiratory volume at first second (FEV1)%, forced vital capacity (FVC)%, FVC/FEV1%) and skin prick tests was performed at baseline. Symptom scores and medication scores were collected during regular follow-up monthly visits along with follow-up lung function tests, after treatment. Out of the patients who received SCIT, 84.9% had an overall successful outcome with complete response in 44.2% (patients who reached maintenance dose with complete absence of allergy symptoms and discontinuation of medications) and partial improvement in 40.7%, whereas 15.1% showed no improvement. There was significant better efficacy of SCIT in cases with asthma alone than in cases with groups of combined airway diseases, and no significant difference in SCIT outcome between cases with asthma alone and cases with allergic rhinitis alone. There was significant better response to SCIT in males than in females and significant better response in the younger age group (5-20 y) than in the older ones. There were no significant differences in the outcome of SCIT in mono-sensitized versus poly-sensitized patients. No serious adverse reactions occurred after SCIT; local pain at injection site in 5.2% patients, grade 1 systemic reactions in 0.9% patients and grade 2 reactions in 1.25% patients were observed. Thus, it can be concluded that SCIT is an effective and safe treatment in selected cases of respiratory allergies.  
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms